Phase I dose escalation study of Linsitinib (OSI-906) and Erlotinib in patients with advanced solid tumors by Macaulay, V, Middleton, M, Eckhardt, S, Rudin, C, Juergens, R, Gedrich, R, Gogov, S, McCarthy, S, Poondru, S, Stephens, A, Gadgeel, S